Charlie Zhou: Exploring the Potential of Immune Reset Therapies in Autoimmune Cytopenias
Charlie Zhou, Head of Portfolio Strategy at Ouro Medicines, shared a post on LinkedIn about the recent article he and his colleagues co-authored, adding:
“It’s been a privilege to collaborate with some of the preeminent experts in autoimmune cytopenias on this review examining the potential of immune reset therapies to change the treatment landscape for these debilitating conditions.”
Title: Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies
Authors: David J. Kuter, Sigbjørn Berentsen, Nichola Cooper, Lei Zhang, Jun Shi, Yunfei Chen, Lele Zhang, Charlie Zhou, Yanrong Wang, Jaideep S. Dudani, Neelufar Mozaffarian
Read the Full Article on Blood Reviews
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 11:56William Pao: Celebrating a Landmark Breakthrough in Hemophilia Care
-
Sep 10, 2026, 11:25Andreas Glenthøj: New Sickle Cell Trait Data in UpToDate
-
Sep 10, 2026, 10:53A New Era of Hemophilia Screening and Diagnosis in Women and Girls – ISTH
-
Sep 10, 2026, 10:03Investing in Youth, Transforming Hemophilia Care – WFH
-
Sep 10, 2026, 09:51Ronke Oke BEM: 20 Years of Newborn Sickle Cell Screening in England
-
Sep 10, 2026, 09:41Seunghwan Song: Hemlibra and the Science That Changed Hemophilia A Care
-
Sep 10, 2026, 09:20Mark Dawson: A Radical Rethink of Hemophilia Treatment
-
Sep 10, 2026, 07:26Carly Newton: Every Donation Helps Save Lives
-
Sep 10, 2026, 07:152023 ACR/EULAR APS Classification Criteria – APS Foundation of America